Project 2025 vs. The Public’s Health Part I: The CDC

MicrobeTV

P. Offit, V. Racaniello

Artificial Intelligence Liability Issues: A Primer

Kathleen G. Healy

Year in Review: Preparing Residents for a Positive and Ethical Relat…

Dermatology 2024 Year in Review

N. Bhatia

ASH 2024 Review: Key Updates in Hodgkin Lymphoma

Cleveland Clinic Taussig Cancer Institute

M. Gallogly

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Misinformation in ITP

Platelet Disorder Support Association (PDSA)

D. Nugent

ASH 2024 Insights: Incorporating Nivolumab and Brentuximab Vedotin I…

2024 ASH Annual Meeting Insights Hub

A. LaCasce

ASH 2024 Insights: Pembro Maintenance instead of ASCT for Pts With R…

Memorial Sloan Kettering Cancer Center

A. Moskowitz

ASH & ISHL 2024 Summary: Key Clinical Questions & Highlights in cHL

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

Current Treatment of 1L Hodgkin Lymphoma

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

Guiding Patients in End-Of-Life Preparation

Lydia Dugdale

ASH 2024 Treatment Updates in Lymphoma: Practice Changing and Promis…

UChicago Medicine

A. Rojek

ASCO® 2024 Summary: "Treatment of Relapsed HL - Updated Options in L…

2024 ASCO® Annual Meeting Insights Hub

P. Johnson

Treatment Updates and Management of Hodgkin Lymphoma

Integrity CE

A. Niu, D. Wallace, M. Cortese

Landmark Clinical Trial Insights: SWOG S1826 for Advanced Stage cHL …

OncoPharm

J. Bossaer

Clinical Application of Practice-Changing SWOG S1826 Trial: Nivo+AVD…

Moffitt Cancer Center

Y. Zhang, B. Shah, J. Chavez, M. Jain, S. Gaballa

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual